Időskori makuladegeneráció: vizsgálatok itt: Örményország

1 trial · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.

• 2. fázisTaking people
  A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

  Where

  Yerevan

  Életkor

  55 év to 64 év

  People

  110 worldwide

  Run by

  Galimedix Therapeutics Inc

  See details and how to joinNCT06659549 · EU 2024-519128-26-00